Hydantoins are often reported as potent anticonvulsant drugs; however, recent studies have highlighted their antinociceptive potential. Based on these reports, this study investigated the antinociceptive and anti-inflammatory activities of the hydantoin derivative 5-(4-isopropylphenyl)-3-phenyl-imidazolidine-2,4-dione (IM-7) using animal models. Treated mice submitted to the acetic acidinduced writhing test showed increase (p<0.01 or p<0.001) in the latency to the first writhing and reduction in the number of abdominal writhing (p<0.001). Furthermore, all doses reduced the nociceptive response in the first (p<0.05 or p<0.001) and second (p<0.001) phases of the formalin test. This effect was inhibited by pretreatment with the antagonists naloxone, sulpiride and caffeine. Additionally, IM-7 (75, 150 and 300 mg/kg, i.p.) reduced (p<0.05 or p<0.001) the glutamate-induced nociceptive response. Carrageenan-induced paw edema was strongly reduced following treatment with all doses of IM-7 (p<0.05, p<0.01 or p<0.001), and so were leukocyte migration and levels of interleukin-1β (300 mg/kg: p<0.001) and tumor necrosis factor-α (300 mg/kg: p<0.01) in carrageenan-induced peritonitis. Therefore, IM-7 decreased the nociceptive response via a mechanism involving the opioid, dopaminergic, and adenosinergic receptors. Its anti-inflammatory action also contributed by decreasing the release of pro-inflammatory cytokines.
INTRODUCTION
Pain is the symptom that most often leads patients to seek medical care (Rief et al., 2012) . It currently affects about 100 million Americans, generating an estimated economic impact of 560 to 635 billion dollars per year (Dubois and Follett, 2014) . Although there is an extensive therapeutic arsenal available for the treatment of pain, it is accompanied by a range of undesirable side effects. Some examples include the gastric irritation that can ensue as a result of non-steroidal anti-inflammatory drug (NSAID) usage or opioid tolerance. This issue is, therefore, one of the factors that motivates research into the development of new drugs for pain relief.
It has been reported previously that anticonvulsants may be useful in some painful conditions such as trigeminal neuralgia and diabetic neuropathy (Bhattacharya et al., 2009) . Phenytoin, for example, blocks presynaptic voltage-gated sodium channels, thereby inhibiting the pathological release of excitatory neurotransmitters, such as glutamate, which are directly involved in nociceptive pathways (Sakaue et al., 2004; Webb and Kamali, 1998) . This drug belongs to the class of drugs known as the hydantoins, which are compounds with a chemical structure containing a derivative of the imidazolidine ring. These substances have been extensively studied, both in regards to their chemical structure and their pharmacological properties. Some of these properties include acting as a muscle relaxant, antiarrhythmic, antibacterial, antitumor and, particularly, anticonvulsant (Oliveira et al., 2008) .
While studies investigating the anticonvulsant activity of hydantoins are common in the scientific literature, especially because of the established efficacy of phenytoin against partial and generalized tonic-clonic seizures, increasing efforts have been undertaken to characterize the antinociceptive profile of new hydantoins. Behavioral studies have demonstrated that hydantoins are able to reduce nociceptive behavior and inflammation in animal models (Guerra et al., 2011; Sudo et al., 2010; Sztanke et al., 2005; Walls et al., 2012) . These results were similar to those observed by our research group in mice subjected to the acetic acidinduced writhing test, formalin and hot plate tests, and carrageenan-induced peritonitis after treatment with the hydantoin derivatives IM-3 and HPA-05 (Maia, 2013; Queiroz et al., 2015; Salgado, 2011) .
Studies concerning the antinociceptive effects of hydantoins are still scarce; however, there is a strong indicator of the potential of these substances. Thus, in this study the antinociceptive and anti-inflammatory properties of the hydantoin derivative 5-(4-isopropylphenyl)-3-phenyl-imidazolidine-2,4-dione (IM-7) were investigated in mice.
MATERIALS AND METHODS

Hydantoin derivative IM-7
The synthetic compound IM-7 was provided by Prof. Dr. Petrônio Filgueiras de Athayde Filho (Organic Synthesis Laboratory, Federal University of Paraíba, Brazil). Synthesis was performed as previously described (de Sousa et al., 2009 ).
Animals
Male Swiss mice (25 to 35 g, approximately 3 months old) were obtained from the vivarium of Prof. Dr. Thomas George (UFPB), where they were monitored and kept at a constant temperature (21 ± 1°C), exposed to light/dark cycles of 12 h each (light phase from 0600 to 1800), and given water and food ad libitum. Animals were used only once and euthanized at the end of each experiment. All procedures were approved by the Animal Experimentation Ethics Committee (CEPA/UFPB/BRAZIL, protocol number 0601/11).
Drugs and reagents
The following materials were used: Acetic acid (Reagen, Brazil); cytokines assay kits (e-Bioscience, USA); atropine, bicuculline, caffeine, carrageenan, dexamethasone, glibenclamide, glutamate, sulpiride and yohimbine (Sigma, USA); formaldehyde P.A. (Vetec, Brasil); morphine hydrochloride (Merck, USA) and naloxone hydrochloride (Research Biochemical, USA). The substances were solubilized in distilled water (LTF/UFPB, Brazil) and administered intraperitoneally (i.p.) at 0.1 mL per 10 g of body weight (except formaline, glutamate and carrageenan: 20 μL, via intraplantar; and naloxone and dexamethasone used subcutaneously). IM-7, glibenclamide and sulpiride were dissolved in Tween 80 (Vetec, Brazil) and distilled water.
Evaluation of the antinociceptive activity of IM-7
Acetic acid-induced writhing test
The injection of 0.85% acetic acid into the peritoneal cavity of mice triggers a nociceptive response characterized by abdominal contortions followed by stretching of the hind limbs (Koster et al., 1959) . Mice were distributed into groups (n=8), and treated with a vehicle (3.4% v/v Tween 80), morphine (10 mg/kg), or IM-7 at doses of 75, 150, and 300 mg/kg. After 30 min (morphine treatment group) or 60 min (vehicle and IM-7 treatment groups), the animals were administered an intraperitoneal (i.p.) injection of 0.85% acetic acid (0.1 mg/mL) and were observed for 15 min. The latency to the first writhing and the number of abdominal contortions that occurred in the interval of 5 to 15 min after the administration of acetic acid were recorded. A decrease in the number of contortions was considered indicative of an antinociceptive effect.
Formalin test
This methodology, described by Dubuisson and Dennis (1977) and adapted by Hunskaar et al. (1985) for mice, involves inducing nociception by the subcutaneous (s.c.) injection of formalin 2.5% (20 µl) into the hind paws of mice. Animals respond to this stimulus by licking the injected paw, and the time spent in this activity is recorded in 2 phases. The first phase (0 to 5 min) occurs due to the direct stimulation of nociceptors, while the second phase (15 to 30 min) involves the participation of inflammatory mediators. Mice were distributed into groups (n=8), and injected with a vehicle 150 , and 300 mg/kg). An intraplantar (i.pl.) injection of formalin 2.5% (20 µL) was administered into the right hind paw of the mice 30 min (morphine group) or 60 min (vehicle and IM-7 groups) after treatment. The times spent in the 2 phases were recorded.
Glutamate-induced nociception
Glutamate is the major excitatory neurotransmitter involved in nociceptive signal transmission (Beirith et al., 2002) . In order to evaluate the influence of IM-7 on the glutamatergic system, mice were treated with an i.p. injection of a vehicle (3.4% v/v solution of Tween 80) or IM-7 (75, 150, or 300 mg/kg). After 60 min, 20 μl of glutamate solution (20 μmol/paw) was injected into the right hind paw of the mice. Animals were immediately placed into individual observation boxes and the nociceptive response (paw licking time) was recorded for 15 min.
Mechanism of action
To demonstrate the possible mechanism of action involved in the IM-7-induced antinociceptive effect we used pharmacological tools and formalin. Briefly, 15 min prior to treatment with IM-7 (75 mg/kg, i.p.), pattern drugs were administered to the mice. These included naloxone (5 mg/kg, s.c.), an opioid receptor antagonist; glibenclamide (10 mg/kg, i.p.), an ATP-sensitive potassium channel (KATP) blocker; sulpiride (20 mg/kg, i.p.), a D2 dopamine receptor antagonist; yohimbine (0.15 mg/kg, i.p.), an α2-adrenergic receptor antagonist; atropine (5 mg/kg, i.p.) a muscarinic receptor antagonist; bicuculline (1 mg/kg, i.p.)a gamma amino butyric acid-A receptor (GABAA) antagonist; and caffeine (10 mg/kg, i.p.), an adenosine receptor antagonist.
Evaluation of the anti-inflammatory activity of IM-7
Carrageenan-induced paw edema
The injection of carrageenan elicits an inflammatory reaction characterized by edema, erythema, and hyperalgesia, which can be reversed by steroid and non-steroid anti-inflammatory agents (Winter et al., 1962) . Mice were distributed into groups (n=8) and treated as follows: negative control group, 3.4% v/v Tween 80, i.p.; positive control group 3.4% v/v Tween 80, i.p. and IM-7 (75 mg/kg, i.p.); IM-7 (150 mg/kg, i.p.); IM-7 (300 mg/kg, i.p.); and dexamethasone (2 mg/kg, s.c.). Mice received 20 μL of a 1% solution of carrageenan in the subplantar region of the right hind paw and 20 μL of saline into the left hind paw 60 min after treatment. The negative control group received saline in both paws (data not shown). Hind paw thickness was recorded for each mouse with a digital micrometer just before carrageenan injection (baseline measurement, data not shown), and then after 1, 2, 3, 4, 5, 24, 48, and 72 h. Edema was calculated as the difference between right and left hind paw thickness.
Carrageenan-induced peritonitis
Carrageenan-induced peritonitis was used to determine if IM-7 could inhibit cell migration that results from the animal's exposure to an acute inflammatory stimulus. Mice (n=6) were distributed into groups and treated with a vehicle (3.4% v/v Tween 80); IM-7 at 75, 150, or 300 mg/kg i.p.; or dexamethasone (2 mg/g, s.c.). After 60 min, the inflammatory process was induced by an i.p. injection of 1% carrageenan. Four hours later, animals were euthanized and de Carvalho et al. 759
the peritoneal exudate was removed after washing the peritoneal cavity with 3 mL of phosphate buffered saline (PBS). The peritoneal exudate was centrifuged at 1500 rpm for 5 min at 4°C, and the supernatant was stored at -20°C for further measurement of the pro-inflammatory cytokines. Precipitated cells were diluted with Turk's solution (1:10) to determine the total cell count in a Neubauer chamber under an optical microscope.
Differential cell counts in the peritoneal exudate
For each animal, the peritoneal exudate was diluted 1:10 in PBS and 100 μL of this cell suspension was cytocentrifuged (Citopin, Bio Research) at 1500 rpm for 15 min to prepare slides. The slides were then stained with May-Grunwald Giemsa to allow differential cell counts of polymorphonuclear and mononuclear leukocytes using an optical microscope.
Pro-inflammatory cytokine assay
Tumor necrosis factor (TNF)-α and interleukin (IL)-1β levels in the peritoneal fluid were assessed using specific cytokine ELISA assay kits and a microplate reader set at 450 nm (VERSAmax Tunable, Molecular Devices). The protocol was performed according to the manufacturer's instructions. The levels of cytokines were calculated from the standard curves and expressed as the total amount per milliliter (pg/ml).
Statistical analysis
Differences between the means of the groups were evaluated by one-way analysis of variance (ANOVA), followed by Dunnett's test or Tukey's multiple comparisions test depending on the case. Results were expressed as the mean ± standard error of mean (SEM) and considered significant when p <0.05.
RESULTS
Effects of IM-7on the acetic acid-induced writhing test
The latency to the first writhing was significantly increased in mice treated with doses of 75 mg/kg (357.4 ± 34.6 s; p <0.05), 150 mg/kg (518.5 ± 87.9 s; p <0.01) and 300 mg/kg (767.9 ± 71.2 s; p <0.001) of IM-7 when compared to the control group (221.3 ±15.0 s) ( Figure  1A ). The number of contortions decreased in animals treated with IM-7. While the vehicle-treated group showed an average of 44.8 ± 4.0 contortions, the groups treated with doses of 75, 150, and 300 mg/kg IM-7 exhibited 16.8 ± 3.5, 7.1 ± 2.9, and 2.6 ± 2.0 contortions during the 10 min of observation, respectively ( Figure  1B ). Animals treated with morphine (10 mg/kg, i.p.) exhibited no abdominal contortions.
Effects of IM-7 on formalin-induced nociception
According to data shown in Figure 2A , in the first phase of this test all doses of IM-7 (75, 150, and 100 mg/kg, i.p.) were able to reduce the paw licking time (37.8 ± 7.6 s, 37.8 ± 8.6 s, and 14.4 ± 3.6 s, respectively) when compared to the control group (65.8 ± 5.7 s). A similar reduction was observed with morphine (14.3 ± 6.9 s). In the second phase, the paw licking time also decreased significantly (p <0.001) at all tested doses of IM-7 when compared to the control group (165.9 ± 22.7 s). The obtained values for mice treated with doses of 75 and 150 mg/kg were 21.1 ± 16.8 and 5.5 ± 4.7 s, respectively. Animals that received morphine or IM-7 at the dose of 300 mg/kg did not lick their paws in this phase ( Figure  2B ).
Effect of IM-7 on glutamate-induced nociception
At all tested doses, IM-7 (75 mg/kg, 16.1 ± 5.1 s; 150 mg/kg, 16.3 ± 8.1 s; 300 mg/kg, 0.75 ± 0.4 s) significantly inhibited nociceptive behavior induced following intraplantar injection of glutamate in mice, when compared to the vehicle-treated group (42.1 ± 9.7 s, p <0.05, Figure 3) .
Investigation of the mechanism of action of IM-7
The pretreatment of mice with naloxone (5 mg/kg, s.c., opioid receptor antagonist), sulpiride (20 mg/kg, i.p., D2 dopamine receptor antagonist) or caffeine (10 mg/kg, i.p., adenosine receptor antagonist) 15 min prior to the administration of IM-7 (75 mg/kg, i.p.) significantly inhibited the antinociceptive response induced by IM-7 in the first phase of the formalin test (Figure 4) . However, the pretreatment with glibenclamide (10 mg/kg, i.p., K ATP channel blocker), atropine (5 mg/kg, i.p., muscarinic receptors antagonist), yohimbine (0.15 mg/kg, i.p., α 2 -adrenergic receptor antagonist) or bicuculline (1 mg/kg, i.p., GABAA receptor antagonist) did not alter the effect of IM-7 in this test (Figure 4 ).
Effect of IM-7 on carrageenan-induced paw edema
As shown in Figure 5 , the administration of IM-7 (i.p.) significantly inhibited carrageenan-induced paw edema from the first hour after carrageenan injection until the fifth hour of observation at all tested doses (p <0.05). This effect persisted until 24 h at a dose of 150 mg/kg, and until 48 h in mice treated with 300 mg/kg.
Effect of IM-7 on carrageenan-induced cellular influx into the peritoneal cavity
As shown in Figure 6 , leukocyte migration induced by intraperitoneal carrageenan administration (8.0 ± 0.6 × Figure 5 . Effect of IM-7 on carrageenan-induced paw edema in mice. Results are shown as mean ± S.E.M., and the % of inhibition when compared to control group is shown in parenthesis ANOVA one-way followed by Tukey's multiple comparisions test. *p<0.05; **p<0.01; ***p<0.001 versus vehicle-treated group. 10 6 cells/mL) was significantly reduced following treatment with 300 mg/kg of IM-7 (2.8 ± 0.5 × 10 6 cells/mL; p <0.001). This effect seems to be due to the reduction of the influx of both polymorphonuclear (control, 5.8 ± 0.7 × 10 6 cells/mL; IM-7 300 mg/kg, 2.0 ± 0.5 × 10 6 cells/mL; p <0.01) and mononuclear (control, 2.2 ± 0.3 × 10 6 cells/mL; IM-7 300 mg/kg, 0.9 ± 0.1 × 10 6 cells/mL; p <0.05) cells into the peritoneal cavity. Treatment with doses of 75 and 150 mg/kg of IM-7 did not show significant decreases in cellular migration in this model. Figure 7 shows that intraperitoneal injections of carrageenan significantly increased the amount of the pro-inflammatory cytokines TNF-α (326.4 ± 51.7 pg/mL) and IL-1β (69.1 ± 7.2 pg/mL) in peritoneal exudate when compared to the saline group (10.6 ± 0.3 pg/mL and 12.1 ± 1.0 pg/mL, respectively). Treatment with 300 mg/kg of IM-7 significantly reduced the TNF-α level (93% decrease; p <0.001) when compared to the control group. At the same dose, IM-7 also reduced the IL-1β level (58% decrease; p <0.01) in the peritoneal exudate. Dexamethasone (2 mg/kg), a well-known antiinflammatory drug, reduced both TNF-α (82% decrease; p <0.001) and IL-1β (41% decrease; p <0.05) levels.
Effect of IM-7 on pro-inflammatory cytokine levels in the peritoneal fluid
DISCUSSION
In this study, the antinociceptive and anti-inflammatory effects of the hydantoin derivative, IM-7 in mice were investigated. It was observed that i.p. treatment of mice with IM-7 to decrease the number of abdominal contortions induced by the intraperitoneal injection of 0.85% acetic acid. The injection of i.p. acetic acid enhances the release of several pro-inflammatory mediators such as prostaglandin (PG)E 2 , PGF 2α , TNF-α, IL-1β, and IL-8 (Deraedt et al., 1980; Ribeiro et al., 2000) . Additionally, it also enhances the release of the excitatory neurotransmitters, aspartate and glutamate, in the cerebrospinal fluid by sensitizing and stimulating primary afferent neurons (Gu et al., 2013) .
Despite its high sensitivity to centrally and peripherally acting drugs, the acetic acid-induced writhing test has poor specificity. This is due to substances lacking analgesic effects, like sedatives, antidepressants, antihistamines, muscle relaxants, and neuroleptic agents, being able to inhibit abdominal writhing and, therefore, producing false-positive results (Le Bars et al., 2001 ). On the other hand, the formalin test, a widely used model of persistent pain, is more selective and permits the differentiation between 2 types of antinociceptive mechanisms: neurogenic and anti-inflammatory (Hunskaar et al., 1985 (Hunskaar et al., , 1987 .
The antinociceptive effect of IM-7 was also detected by the formalin test, since all tested doses significantly reduced the paw licking response in both phases, in similarity to morphine. Centrally acting drugs such as opioids inhibit both phases of the formalin test, while peripherally acting drugs, such as NSAIDs and corticosteroids, only inhibit the second phase (Hunskaar et al., 1987) . Thus, these results demonstrated that IM-7 exerts effects both at the central and peripheral level, by interfering with direct nociceptive and inflammatory mediators or receptors. Glutamate is the major excitatory neurotransmitter involved in nociceptive signal transmission. Beirith et al. (2002) demonstrated that the intraplantar injection of glutamate into the mouse paw produces a nociceptive response (licking) and paw edema. These effects seem to be mediated by both ionotropic and metabotropic glutamate receptors and involve peripheral, spinal, and supraspinal sites. When given intraperitoneally, IM-7 significantly inhibits the nociceptive response induced by the peripheral injection of glutamate. To further characterize the underlying mechanisms of the antinociception induced by IM-7, a series of antagonists/blockers of known pathways involved in pain regulation were employed. The antinociceptive response induced by IM-7 in the formalin test was significantly inhibited by the pretreatment of mice with naloxone, caffeine, or sulpiride. This supports the proposal that opioid, adenosine, and D2 dopamine receptors play a role in the mechanism of action of IM-7, since their activation reduce the transmission of nociceptive impulse. Pretreatment with atropine, yohimbine, bicuculline, or glibenclamide did not modify the antinociceptive effect induced by IM-7, therefore, eliminating the participation of muscarinic, α 2 -adrenergic, and GABA A receptors, as well as K ATP channels. However, Sudo et al., (2010) demonstrated the involvement of α 2A -adrenergic receptors in the antinociceptive response evoked by the hydantoin derivative PT-31 in mice. In their study, pretreatment with yohimbine or BRL 44408 (selective α 2A -adrenergic receptor antagonists) significantly reduced the effect of PT-31. These results explain only the central antinociceptive mechanism of IM-7, since all antagonists/blockers failed to inhibit the effect of this hydantoin on the second phase of the formalin test. This could be explained by the involvement of antiinflammatory mechanisms on the antinociceptive activity of IM-7.
Edema formation resulting from the increase in vascular permeability and vasodilatation of the arterioles (Szolcsányi, 1988) allows sensory neurons to release active mediators in the inflammatory process. These substances released by stimulated neurons are considered the neurogenic component of inflammation mediation (Fantini et al., 1995; Maggi and Meli, 1988) . This means that the formation of edema is the major consequence of neurogenic inflammation (Bon et al., 2013) . The obtained results demonstrated the significant inhibition of paw edema post-carrageenan injection by IM-7 at different times. One of the mechanisms by which this can happen is through the direct blocking of a receptor that contributes to the edema formation, such as transient receptor potential ankyrin 1 (Moilanen et al., 2012) , a non-selective cation channel whose activation contributes to the increased excitability of nociceptors and neurogenic inflammation (Story et al., 2003) . It is noteworthy that the inflammatory response induced by carrageenan in this model is biphasic. The first phase lasts approximately 6 h and is mediated by the release of histamine, serotonin, and kinins. The late phase involves the release of prostaglandins and is characterized by more pronounced edema that starts approximately 24 h after administration of carrageenan, with peak at 72 h (Henriques et al., 1987; Shibata et al., 1989) . All the doses of IM-7 inhibited paw edema in the first 5 h of observation. Furthermore, treatment with doses of 150 mg/kg and 300 mg/kg of IM-7 inhibited paw edema by 53 and 83%, respectively, 24 h after the administration of carrageenan. After 48 h, the inhibitory effect of the 300 mg/kg dose could still be detected, with an inhibition of 60%. However, after 72 h, there was no significant inhibition resulting from IM-7 treatment at the tested doses. According to these results, it seems that IM-7 can inhibit the inflammatory process by reducing the release of mediators involved in both phases of carrageenaninduced paw edema. Guerra et al. (2011) observed that some hydantoins reduce leukocyte migration and inhibit TNF-α and IL-1β release in air pouch and peritonitis models. At least in part, these anti-inflammatory effects may be attributed to the selective and potent inhibition of the TNF-α converting enzyme (TACE), responsible for the activation of TNF-α Yu et al., 2010) or inhibition of the nuclear factor (NF)-kappaB pathway (Wang et al., 2015) .
In this study, IM-7 also reduced leukocyte migration and inhibited TNF-α and IL-1β release induced by carrageenan in a peritonitis model; therefore, reinforcing the anti-inflammatory activity of this hydantoin.
Conclusion
The results of this study strongly suggest that the acute intraperitoneal injection of the hydantoin derivative IM-7 in mice induces a dose-dependent antinociceptive response. This response is probably mediated by its interaction with opioid, dopaminergic, and adenosinergic receptors, along with its anti-inflammatory activity resulting in reduced leukocyte migration and TNF-α and IL1-β release.
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